HALO Maintained by TD Cowen -- Price Target Raised to $130

gurufocus.com · 2026-10-13

Halozyme Therapeutics (HALO) Analyst Rating Update On October 13, 2026, TD Cowen maintained its "Buy" rating for Halozyme Therapeutics (HALO) while raising t

TickrTrends take: TD Cowen's raise of HALO's price target to $130 reflects analyst confidence in the company's fundamentals within the Healthcare sector. Given that TickrTrends currently categorizes HALO as undervalued, this analyst action suggests there may be a gap between the market's current pricing and what research professionals view as justified valuations. Valuation-focused readers should monitor whether this price target adjustment influences market perception and helps close any valuation gap identified by TickrTrends.

Read the full story at gurufocus.com →